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C.L. Batlevi et al. / European Journal of Cancer 126 (2020) 78e90 79with rituximab-based chemotherapy. Patients (N Z 484) from the FOLL05 study served as an
independent validation cohort. We risk-stratified patients based on pre-treatment radio-
graphic imaging (positron-emission tomography [PET] versus computed tomography [CT])
and early POD status using event-defining and landmark analyses. A competing risk analysis
evaluated the association between early POD and histologic transformation.
Results: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-
CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for
PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD
was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic
transformation in patients whose disease progressed within one year of initiating therapy
was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respec-
tively), which was associated with a 9.7-fold higher risk of death.
Conclusion: In FL, pre-treatment PET staging reduced the prognostic impact of early POD
compared with CT staging. Patients with early POD and no histologic transformation have
an extended OS with standard therapy.
ª 2019 Elsevier Ltd. All rights reserved.1. Introduction
FL is the second most common lymphoma in the United
States, compromising approximately 30% of all lym-
phomas [1,2]. As treatment outcomes and OS continue
to improve, surrogate end-points are increasingly
needed to predict OS in prospective clinical trials.
Previous studies proposed early progression or an
early event was the surrogate end-point predicting poor
OS in patients with newly diagnosed FL. In one study,
patients with FL whose disease progressed within 24
months from diagnosis (progression-free survival at 24
months [PFS24]) after treatment with rituximab,
cyclophosphamide, doxorubicin, vincristine and pred-
nisone (R-CHOP) had a 5-year OS of 50%, compared
with 90% for those without early POD [3]. In a
different study, patients with an event within 12
months (event-free survival at 12 months) after treat-
ment with immunochemotherapy also had a poor OS
[4]. These two studies shared similar but distinct defi-
nitions of early POD. One study based the analysis on
event-free survival, which included the start of new
lymphoma therapy as an event, whereas the other study
used progression-free survival; therefore, early POD
lacks a common definition. Nonetheless, the studies
identified patients with early POD as a subgroup of
patients with FL with inferior outcomes and repre-
sented an area of unmet medical needs. These obser-
vations suggested utilisation of a new clinical end-point
to evaluate new treatment strategies, possibly leading
to rapid approval by regulatory agencies. Furthermore,
these observations suggested more intensive treatment
approaches, including salvage chemoimmunotherapy
followed by consolidative autologous stem celltransplantation, may be needed to improve the treat-
ment outcome [3,5,6].
However, the imaging modality used at diagnosis and
before treatment initiation in the earlier studies was not
described [3,4]. Whether the prognostic significance is
maintained in the PET-based staging era is currently
unknown. PET with 2-[18F]-flouro-2-deoxyglucose inte-
grated with CT (FDG-PET, hereafter referred to as
PET) has emerged as an important imaging tool for
staging, response assessment and predicting treatment
outcomes of FL [7]. PET imaging is more sensitive than
CT imaging in identifying extranodal disease and facil-
itates more accurate clinical staging or response assess-
ment [8e11]. Furthermore, several studies highlight the
ability of PET imaging to identify sites of suspected
transformation for targeted biopsy, which may influence
the choice of initial therapy and treatment outcome
[12e15].
With this background, we examined the impact of
PET staging on the treatment outcome and prognosis of
FL. We also compared the prognostic significance of
PFS24 after first-line therapy in patients with FL whose
disease was assessed by CT or PET imaging modalities.2. Methods
2.1. Study design
This is a retrospective study of adult patients (aged 18
years) diagnosed between the years of 1998 and 2009
with FL managed at Memorial Sloan Kettering Cancer
Center (MSKCC). This time frame was selected to
include patients who were treated in the rituximab era
C.L. Batlevi et al. / European Journal of Cancer 126 (2020) 78e9080and to allow adequate follow-up. The institutional re-
view board approved this study.
2.2. Participants
Patients with FL grade IIIB, composite histology or de
novo disease transformation at diagnosis, with fewer
than 3 clinic visits (indicative of a consultative role
without long-term follow-up) or harbouring an active
concurrent malignancy were excluded. For the MSKCC
cohort, pathology slides were confirmed at MSKCC.
Radiographic modality used for staging was captured at
both diagnosis and at the time of first treatment.
Transformation to diffuse large B cell lymphoma
(DLBCL) at the time of relapse was confirmed by bi-
opsy. From a database of 1088 patients with FL (grade
I, II and IIIA), we excluded 31 patients with histologic
transformation to DLBCL before treatment; 164 pa-
tients were observed and did not require treatment.
Eight hundred ninety-three patients were evaluable at
first treatment; of which, 754 patients had stage IIeIV
disease (Fig. 1). We identified 346 patients with stage
IIeIV grade IeIIIA FL treated with rituximab and
chemotherapy for analysis of the impact of PFS24 status
on OS: 118 patients with pre-treatment CT and 228
patients with pre-treatment PET (Fig. 1). A subgroup of
238 patients with stage IIeIV grade IeIIIA FL who
were initially treated with R-CHOP chemotherapy were
identified for separate analysis: 84 patients with pre-
treatment CT and 154 patients with pre-treatment PET.
An independent cohort of 484 patients with FL treated
with rituximab-based chemotherapy regimens between
2006 and 2010 in the prospective FOLL05 clinical trial
conducted by the Fondazione Italiana Linfomi was used
for validation [16,17]. From the FOLL05 study, 161
patients with FL treated with R-CHOP were identified
for replication: 114 patients with pre-treatment CT and
47 patients with pre-treatment PET.
2.3. Statistical analysis
PFS24 failures were defined as patients with disease
progression within 24 months of treatment initiation
(PFS24). PFS24 achievers were defined as patients
without disease progression within 24 months of treat-
ment initiation. We selected time of initiating therapy
instead of time of diagnosis as our landmark because
our population included patients who were initially
managed with observation but who subsequently
required therapy. Two methods were used indepen-
dently to risk stratify patients based on early progres-
sion status. First, we conducted an event-defining
analysis to directly compare with the methods previ-
ously followed by by Casulo et al. [3] and Maurer et al.
[4]. Accordingly, OS for PFS24 failures was defined as
the time from PFS24 failure to death or last follow-up.
OS for the PFS24 achievers was defined as the survivaltime from achieving PFS24 (i.e. 24 months after treat-
ment initiation) until death or last follow-up. Patients
were excluded from this analysis if they died within 24
months without disease progression or were lost to
follow-up within 24 months of first-line therapy. Second,
we used a landmark analysis proposed by
Anderson et al. [18] to compare the outcomes of the
PFS24 failures and PFS24 achievers. Using a common
time origin for both groups allows comparison of out-
comes to be more clinically interpretable and eliminates
immortal time bias that arises when an event such as
relapse occurs during the time of follow-up [18]. OS in
the landmark analysis was calculated from 24 months
after treatment initiation to last follow-up or death.
Patients were excluded from the landmark analysis if
they died from any cause or were lost to follow-up
within 24 months of starting first-line therapy.
KaplaneMeier methods were used to estimate survival
probability.
To understand the association between early pro-
gression and transformation, we conducted a competing
risk analysis for patients treated with rituximab-based
chemotherapy (R-CHEMO), in which a patient can
experience one of the two different events: trans-
formation or death without transformation. The time
origin was set at the time of progression or two years for
patients who were progression-free for two years. The
cause-specific event rates were estimated for three
groups of patients: those who progress in the first year,
those who progress in the second year or those who are
progression-free in the first 2 years. The rate of death
without transformation is compared with the survival
rates from the risk-defining event to quantify the rates of
death after transformation within the time interval of
interest [19].
Continuous variables were summarised by medians
and ranges. Categorical variables were summarised by
frequencies and percentages. OS and PFS were esti-
mated using the KaplaneMeier method and compared
using log-rank tests. All tests are two-sided. P values less
than or equal to 0.05 were considered statistically sig-
nificant. All statistical analyses were conducted using
R3.5.0 [20].3. Results
The median age of all 1088 patients was 57 years (range:
20e94). The median follow-up of the population was 8.3
years (range: 0.2e17.5), was 9.5 years (range: 0.3e17.5)
for patients staged with CT and was 7.9 years (range:
0.2e17.2) for patients staged with PET. There was a
trend of increased utilisation of PET imaging over time
(Supplemental Fig. 1).
In the MSKCC cohort, patients were not evaluable if
they had incomplete radiographic records (N Z 57),
missing treatment data (N Z 1), were deceased within
Fig. 1. Consort diagram of patients at initial treatment who were evaluable for progression-free survival (PFS) status at 24 months in the
MSKCC cohort. MSKCC, Memorial Sloan Kettering Cancer Center; CT, computed tomography; PET, positron-emission tomography;
R-CHEMO, rituximab-based chemotherapy; FL, follicular lymphoma; PFS24, progression-free survival at 24 months; R-CHOP, ritux-
imab, cyclophosphamide, doxorubicin, vincristine and prednisone; POD, progression of disease.
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were lost to follow-up (N Z 12) or started second-line
treatment without progression (N Z 11) (Fig. 1). Of
four patients who died within 24 months without pro-
gression, 1 patient died from treatment-related infection,
whereas 3 patients died from causes unrelated to treat-
ment or lymphoma. The 11 patients who started second-
line therapy without progression included 9 patients
who had suboptimal or stable responses to treatment
with associated change of therapy and 2 patients who
suffered treatment toxicity. A total of 346 patients in the
MSKCC cohort who had stage IIeIV disease and were
treated with rituximab and chemotherapy regimens were
evaluable for PFS24 status (Fig. 1, Table 1). Patient
characteristics were similar to those of 754 patients with
stage IIeIV disease who required treatment in the
MSKCC cohort (Supplemental Table 1). The median
age of the 346 patients treated with R-CHEMO was 56
years (range: 24e80 years). Five percent of the patients
had stage II disease, whereas 95% had stage III or IVdisease before treatment initiation. The Follicular
Lymphoma International Prognostic Index (FLIPI) risk
score at the time of treatment initiation was available for
80% of the CT-imaged and 86% of the PET-imaged
patients. A high FLIPI was represented by 45% (154/
346) of patients.
R-CHOP was the primary treatment regimen making
up 71% (N Z 84) of CT-staged and 68% (N Z 154) of
PET-staged patients. Patients not achieving PFS24
represented 30% (N Z 35) of CT-imaged and 28%
(N Z 63) of PET-imaged patients.
The validation cohort consisted of 484 patients from
the FOLL05 clinical trial treated with rituximab in
combination with chemotherapy (Table 1). The median
follow-up for the validation cohort was 6.8 years (range:
0.1e9.9). Nine percent of patients had stage II disease
and 91% of patients had stage III or IV disease at time
of treatment. A high FLIPI was represented by 37% of
the population. Treatment was evenly distributed be-
tween R-CHOP (33%), R-CVP (rituximab,
Table 1
Patient characteristics at treatment initiation.










No. % No. % No. % No. %
Age (years), median (range) 56 (24e80) 55 (23e85) 0.95 55 (29e75) 56 (32e74) 0.24
Gender
Female 54 46% 99 43% 0.73 164 48% 72 52% 0.42
Male 64 54% 129 57% 181 52% 67 48%
Stage
II 6 5% 13 6% 1.00 33 10% 9 6% 0.37
III/IV 112 95% 215 94% 312 90% 130 94%
FLIPI
Low 15 16% 24 12% 0.69 74 21% 31 22% 0.98
Intermediate 30 32% 66 34% 144 42% 57 41%
High 49 52% 105 54% 127 37% 51 37%
Unknown 24 33
LDH
Elevated 31 35% 68 37% 0.89 67 19% 28 20% 0.90
Normal 57 65% 117 63% 278 81% 111 80%
Unknown 30 43
Treatment
R-CHOP 84 71% 154 68% 0.93 114 33% 47 34% 0.85
R-CVP 21 18% 41 18% 116 34% 43 31%
R-FM 1 1% 4 2% 115 33% 49 35%
R-bendamustine 6 5% 14 6%
Other 6 5% 15 7%
Rituximab maintenance
Yes 27 23% 74 32% 0 0% 0 0% 1.00
No 91 77% 154 68% 345 100% 139 100%
Subsequent HDT/SCT 0.84
Autologous 7 6% 20 9% e e
Allogeneic 6 5% 12 5%
Both 3 3% 7 3%
No 102 86% 189 83% e e
PFS24 status
PFS24 achievers 83 70% 165 72% 0.71 235 68% 104 75% 0.16
PFS24 failures 35 30% 63 28% 110 32% 35 25%
CT, computed tomography; PET, positron-emission tomography; PFS24, progression-free survival at 24 months; MSKCC, Memorial Sloan
Kettering Cancer Center; R-CHEMO, rituximab-based chemotherapy; FLIPI, Follicular Lymphoma International Prognostic Index; HDT/SCT,
high-dose therapy and stem cell transplant; LDH, lactate dehydrogenase; R-CHOP, rituximab plus cyclophosphamide, doxorubicin,
vincristine and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine and prednisone; R-FM, rituximab plus fludarabine and
mitoxantrone.
In the MSKCC cohort, 346 patients with stage IIeIV disease treated with R-CHEMO were evaluable for PFS24 status after first-line treatment. In
the validation FOLL05 cohort, 484 patients with stage IIeIV disease treated with R-CHEMO were evaluable for PFS24 status after first-line
treatment.
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and R-FM (rituximab, fludarabine and mitoxantrone;
34%). Patients not achieving PFS24 included 32%
(N Z 110) in the CT-imaged group and 25% (N Z 35)
in the PET-imaged group.
We initially analysed PFS24 based on pre-treatment
radiographic staging in patients treated with R-CHOP
using an event-defining analysis to facilitate comparison
with previously published studies [3,4] (Fig. 2). In the
MSKCC cohort, 238 evaluable patients with stage
IIeIV disease were treated with R-CHOP. PFS24 failure
was observed in 24% (20/84) of CT-imaged and 25% (39/
154) of PET-imaged patients. A replication cohort of
161 patients treated with R-CHOP in the FOLL05 studywas also analysed. PFS24 failure was associated with
inferior OS in the MSKCC cohort regardless of mo-
dality of staging (Fig. 2A). However, the impact of
PFS24 failure on OS was lessened with PET-based
radiologic staging (Fig. 2A). In CT-imaged patients,
PFS24 failures demonstrated an estimated 5- and 10-
year OS of 57.6% (95% confidence interval [CI]:
39e85) and 43.2% (95% CI, 22e86), respectively. In
contrast, patients achieving PFS24 demonstrated an
estimated 5- and 10-year OS of 90.2% (95% CI,
83e98) and 84.0% (95% CI, 75e94), respectively
(Fig. 2A). With PET-based imaging before initiating
treatment, PFS24 failures demonstrated an estimated 5-
and 10-year OS of 70.6% (95% CI, 57e87) and 67.1%
Fig. 2. Event-defining analysis of PFS24 based on radiographic imaging at time of treatment in patients treated with R-CHOP.
KaplaneMeier plots of overall survival (OS) since the risk-defining event stratified by PFS24 status in patients with stage IIeIV disease
treated with R-CHOP. (A) MSKCC cohort. (B) Validation FOLL05 cohort. When comparing OS by PFS24 status, PFS24 failures staged
by CT had a worse outcome than those who were staged by PET. For CT-staged patients who failed to achieve PFS24, the estimated 10-
year OS rate was 43% compared with that of 67% for PET-staged patients. The results were reproduced in the validation cohort in which
CT-imaged PFS24 failures had an estimated 5-year OS rate of 54% compared with PET-imaged PFS24 failures who had an estimated 5-
year OS rate of 100%. MSKCC, Memorial Sloan Kettering Cancer Center; R-CHOP, rituximab, cyclophosphamide, doxorubicin,
vincristine and prednisone; CT, computed tomography; PET, positron-emission tomography; PFS24, progression-free survival at 24
months; HR, hazard ratio.
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achieving PFS24 imaged with PET, the estimated 5- and
10-year OS were 95.0% (95% CI, 91e99) and 83.6%
(95% CI, 73e96), respectively. The FOLL05 validation
cohort confirmed the improvement of the outcome in
PET-imaged patients who failed to achieve PFS24
(P Z 0.857, Fig. 2B).
We next applied a landmark analysis using a 24-
month post-treatment landmark to evaluate the prog-
nosis in patients who are alive but failed to achieve
PFS24. This analysis excluded 7 patients from the
MSKCC cohort and 3 patients from the FOLL05 cohort
for progression before the 24-month landmark.
Applying this method, PET-based staging furtherblunted the impact of PFS24 status on OS, whereas
failure to achieve PFS24 continued to predict a poor OS
in the CT-staged patients (Fig. 3A), In the CT-imaged
patients treated with R-CHOP, PFS24 failures had an
estimated 5- and 10-year OS of 63.2% (95% CI, 44e92)
and 47.4% (95% CI, 24e93) respectively, whereas PFS24
achievers had an estimated 5- and 10-year OS of 90.2
(95% CI, 83e98) and 84.0% (95% CI, 75e94), respec-
tively (Fig. 3A). Patients with PET-based imaging and
who experienced PFS24 failures demonstrated an esti-
mated 5- and 10-year OS of 80.8% (95% CI, 68e96) and
76.1% (95% CI, 62e94), respectively (Fig. 3A),
compared with 95% (95% CI, 91e99) and 83.6% (95%
CI, 73e96) in patients who achieved PFS24 (Fig. 3A).
Fig. 3. Landmark analysis of PFS24 based on radiographic imaging at time of treatment in patients treated with R-CHOP. KaplaneMeier
plots of overall survival (OS) since 2-year landmark stratified by PFS24 status in patients with stage IIeIV disease treated with R-CHOP.
(A) MSKCC cohort. (B) Validation FOLL05 cohort. When comparing OS by PFS24 status, PFS24 failures staged by CT had a worse
outcome than those who were staged by PET. For CT-staged patients who failed to achieve PFS24, the estimated 10-year OS rate was 47%
compared with that of 76% for PET-staged patients. The results were reproduced in the validation cohort in which CT-imaged PFS24
failures had an estimated 5-year OS rate of 56% compared with PET-imaged PFS24 failures who had an estimated 5-year OS rate of 100%.
MSKCC, Memorial Sloan Kettering Cancer Center; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone;
CT, computed tomography; PET, positron-emission tomography; PFS24, progression-free survival at 24 months; HR, hazard ratio.
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cohort (Fig. 3B, Supplemental Table 3).
Next, we investigated whether the data obtained from
R-CHOP could be generalised to other R-CHEMO
regimens. In the MSKCC cohort, we identified 330 pa-
tients treated with R-CHEMO regimens who were
evaluable for the landmark analysis, and 16 patients
were excluded for progression within the 24-month
landmark (Fig. 4). In patients imaged with CT before
treatment, the estimated 5-year OS in patients who
exceeded PFS24 was 92.3% (95% CI, 86.5e98.4)
compared with 62.0% (95% CI, 45.9e83.7) for those not
achieving PFS24 (Fig. 4A). In the PET-imaged patients,
the estimated 5-year OS in patients who exceeded PFS24
was 94.2% (95% CI, 90.4e98.2) compared with 79.4%(95% CI, 68.7e91.7) for those who failed to achieve
PFS24 (Fig. 4A). The validation FOLL05 cohort
included 473 evaluable patients treated with R-
CHEMO, and 11 patients were excluded from the 24-
month landmark. In the CT-imaged patients, the esti-
mated 5-year OS was 95.7% (95% CI, 92.9e98.5) for
patients who exceeded PFS24 compared with 66.9%
(95% CI, 57.6e77.7) for those who failed to achieve
PFS24 (Fig. 4B). In contrast, PET-imaged patients who
exceeded PFS24 had an estimated 5-year OS of 95.6%
(95% CI, 91.5e99.9) compared with 84.3% (95% CI,
72.5e98.0) for those who failed to achieve PFS24
(Fig. 4B, Supplemental Table 4). Patients treated with
R-CHEMO and analysed using the event-defining
analysis supported the pattern that PET-based staging
Fig. 4. Landmark analysis of PFS24 based on radiographic imaging at time of treatment in patients treated with R-CHEMO.
KaplaneMeier plots of overall survival (OS) since 2-year landmark stratified by PFS24 status in patients with stage IIeIV disease treated
with rituximab plus chemotherapy (R-CHEMO). (A) MSKCC cohort. (B) FOLL05 cohort. When comparing OS by PFS24 status, PFS24
failures staged by CT had a worse outcome than those who were staged by PET. For CT-staged patients who failed to achieve PFS24, the
estimated 10-year OS rate was 44% compared with that of 67% for PET-staged patients. The results were reproduced in the validation
cohort in which CT-imaged PFS24 failures had an estimated 5-year OS rate of 67% compared with PET-imaged PFS24 failures who had
an estimated 5-year OS rate of 84%. R-CHEMO, rituximab-based chemotherapy; MSKCC, Memorial Sloan Kettering Cancer Center;
CT, computed tomography; PET, positron-emission tomography; PFS24, progression-free survival at 24 months; HR, hazard ratio.
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in both the MSKCC and the FOLL05 validation co-
horts (Supplemental Fig. 2).
Early disease transformation has been shown to
negatively impact OS in patients with FL [21e24].
Therefore, we performed a competing risk analysis of
transformation and early death to determine if early
transformation after initial treatment is associated with
poor outcomes (Fig. 5). Patients were categorised into
three groups based on their early progression status: (1)
PFS24 achiever, (2) progression within 1 year after
treatment and (3) progression between 1 and 2 years
after treatment. In patients who achieved PFS24, the
cumulative risk of biopsy-proven transformation at 3
years was 3.4%, and all-cause mortality risk at 3 yearswas also 3.4%, with <1% attributed to transformation-
and 2.5% attributed to non-transformationeassociated
causes. For patients who progress within 1 year after
treatment, the cumulative risk of biopsy-proven trans-
formation was 31.9% at 1 year and 42.4% at 3 years. The
all-cause mortality risk was 33%, with almost 60% (18.6/
33) of patient deaths attributed to transformation,
whereas 40% (14.4/33) of patient deaths were unrelated
to transformation. Transformation is a significant
contribution to progression and early death during the
first two years after treatment (Table 2).
In patients staged with CT before treatment, the cu-
mulative risk of transformation at the time of progres-
sion for patients who progressed within 1 year and 1e2
years was 16.7% and 8.7%, respectively. In contrast,
C.L. Batlevi et al. / European Journal of Cancer 126 (2020) 78e9086patients staged with PET before treatment demon-
strated that a lower cumulative risk of transformation at
the time of progression for patients who progressed
within 1 year and 1e2 years was 6.3% and 3.2%,
respectively (Supplemental Table 5). This supports the
hypothesis that PET imaging at diagnosis and treatment
excludes patients with transformation, which previously
would have gone undetected by CT.
4. Discussion
Our study provides evidence of the importance of pre-
treatment PETebased staging in the current manage-
ment of FL. Although early progression remains a
predictor of poor outcomes in FL, the observed differ-
ence in outcomes is blunted in the era of PET-based
staging. Patients who fail to achieve PFS24 and are alive
at 24 months without evidence of transformation may
enjoy a prolonged OS without the need for more
intensive, and potentially more toxic, therapy. In the
MSKCC cohort, less than 20% of patients received a
stem cell transplant at any line of subsequent therapy.
Thirty-eight percent of stem cell transplant recipients
harboured disease transformation. Consistent with our
data, a recent study from MD Anderson Cancer Center
of 342 patients with advanced-stage, grade IeII FLFig. 5. Competing risk analysis to assess association between early pro
CHEMO. Patients were categorised as early progressors within 1 year,
lack progression within 2 years. The competing events were transform
based on time from the risk-defining event (dashed lines) was compa
lines). POD, progression of disease; PFS24, progression-free survival a
rituximab-based chemotherapy; MSKCC, Memorial Sloan Ketteringwithout histologic transformation during their disease
course demonstrated a 5-year OS of >75% regardless of
PFS24 status [25]. The diverse treatment landscape
using a variety of non-intensive, targeted therapy regi-
mens similarly demonstrates favourable OS in patients
with early disease progression but without histologic
transformation [26e33]. For example, a recent update of
the CHRONOS-1 study showed patients with relapsed
or refractory FL, without evidence of disease trans-
formation treated with single-agent copanlisib, demon-
strated similar OS regardless of their PFS24 status [34].
A combined analysis of three clinical trials using
rituximab-based doublets showed a significant but
blunted impact of PFS24 on 5-year OS [5]. Therefore,
caution should be used before considering PFS24
broadly without regard to transformation status as a
surrogate end-point for OS or applying this surrogate
end-point to evaluate the efficacy of new therapeutic
agents.
The discrepancy in OS between CT- and PET-based
imaging in patients with PFS24 failure is likely from a
multitude of factors including improving prognosis
afforded by recent advances and ability of PET-based
imaging to identify areas of disease transformation.
With pre-treatment CT imaging alone, a diagnostic bi-
opsy is typically obtained from a less invasive peripheralgression and transformation in MSKCC patients treated with R-
early progressors between 1 and 2 years and PFS24 achievers who
ation or death without transformation. The risk of transformation
red with the risk of death not attributed to transformation (solid
t 24 months; tFL, transformed follicular lymphoma; R-CHEMO,
Cancer Center.
Table 2
Rate of histological transformation and risk of death based on PFS24 status.















Risk of tFL, % 0.02 (1 week) 9.1 (4) 5.6 (3) 0 (0)
1 31.9 (14) 18.6 (10) 0 (0)
2 34.5 (15) 18.6 (10) 2.1 (5)
3 42.4 (18) 22.7 (12) 3.4 (8)
Risk of death because of tFL, % 0.02 (1 week) 0 (0) 0 (0) 0 (0)
1 11.4 (5) 5.7 (3) 0 (0)
2 16.2 (7) 7.7 (4) 0 (0)
3 18.6 (8) 9.8 (5) 0.9 (2)
Risk of death without tFL, % 0.02 (1 week) 0 (0) 0 (0) 0 (0)
1 9.1 (4) 3.8 (2) 1.2 (3)
2 11.7 (5) 5.8 (3) 1.6 (4)
3 14.4 (6) 12.0 (6) 2.5 (6)
Total risk of death (sum of risk of
death from tFL and without tFL), %
0.02 (1 week) 0 (0) 0 (0) 0 (0)
1 20.5 (9) 9.4 (5) 1.2 (3)
2 27.8 (12) 13.6 (7) 1.6 (4)
3 33.0 (14) 21.8 (11) 3.4 (8)
FL, follicular lymphoma; PFS24, progression-free survival at 24 months; tFL, transformed FL.
Risk of transformed FL denotes the cumulative risk of biopsy-proven transformation at the time of the relapse. The cumulative risk of death
without transformation is provided using a competing risk analysis. The risk of death because of transformation is calculated by the total risk of
death minus the risk of death without transformation.
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areas involved with de novo histologic transformation,
which carries a poor prognosis. With pre-treatment PET
imaging, disease sites with high FDG-PET uptake are
typically biopsied, and if de novo disease transformation
is found, those patients are typically excluded from FL-
based therapy and databases. Accordingly, in our
retrospective data analysis, de novo transformed FL was
not included in the FL database, and this likely
impacted the better OS in our report compared with
other published series.
In our study, we demonstrate that patients who fail to
achieve PFS24 after treatment and undergo histologic
transformation suffered the highest risk of early mor-
tality. In a retrospective pooled analysis with more than
8000 patients with FL, the 5-year survival after trans-
formation was 34% for patients experiencing early (1
year) histological transformation and was 48% for those
with late histological transformation [24]. In addition, a
study by the British Columbia Cancer Agency showed
that 77% of patients treated with rituximab and bend-
amustine with an early progression had a transformative
event [35]. In the PRIMA trial, more than half (58%) of
the transformations were documented during the first
year after induction, and 38% of the biopsies performed
during the first year identified transformations [21].
These results support the hypothesis that the majority of
transformations occur in patients with early progression
after frontline treatment. Co-occurrence of early pro-
gression and transformation is a major contributor to
early mortality. Both studies incorporated subsets of
patients with PET imaging. On early recurrence, PET-based imaging and biopsy is warranted to identify
possible areas of transformation. Admittedly, our data
contrast with results from a GALLIUM substudy that
evaluated patients with PET imaging and showed that
overall transformation in CT-staged patients was 2.5%
and high uptake on PET did not predict
transformation [36].
Limitations of this study include its retrospective
nature, and the histological transformation rate may
also be underestimated because of the lack of systemic
biopsies at the time of progression. In addition, the
blunted prognostic value of PFS24 in the PET era can be
partly attributed to the evolved treatment paradigm in
recent years. Better outcomes were observed from pa-
tients in the FOLL05 cohort than in the MSKCC
cohort. We hypothesised that the survival difference
between the MSKCC and FOLL05 cohorts may be
caused by the nuances in the patient population. For
example, fewer patients in the FOLL05 cohort had a
high-risk FLIPI (37% versus 53%) or elevated levels of
lactate dehydrogenase (20% versus 36%). In addition,
patients enrolled in the FOLL05 clinical trial were
required to have a centrally reviewed pathology sample
which confirmed FL, and a better survival could be
expected by excluding de novo transformed biology.
Both PET- and CT-imaged cohorts demonstrated a
similar absolute rate of PFS24 failures. Ultimately, our
patients were treated with a wide range of first-line and
maintenance strategies over 10 years, therefore evalu-
ating that the absolute rate of PFS24 failure may pro-
vide less nuance than understanding the timing and
transformation status of the relapses. The existing data
C.L. Batlevi et al. / European Journal of Cancer 126 (2020) 78e9088are also not suitable to associate PET utilisation at time
of treatment with identification of transformation before
treatment. However, this may be an important question
to address in the future.
Our study reveals staging with PET imaging at
diagnosis and treatment may provide valuable infor-
mation that impacts the outcomes of patients with FL.
Consistent with previous reports, we found that early
POD in CT-staged patients confers a poor OS. The poor
prognosis associated with early POD is predominantly
driven by early histologic transformation, which can be
missed before initiating therapy in CT-staged patients.
When modern PET imaging was used before initiating
therapy, early POD was less frequently associated with
histologic transformation, and therefore, early POD had
a lower impact on OS. Management of patients with
early progression without histologic transformation
needs to be better studied as this population demon-
strates a more favourable prognosis than patients with
early progression and transformation of disease. Our
study supports the incorporation of PET imaging to
guide clinical decisions in the management of patients
with FL. In addition, our study highlights the need for
repeated biopsies in patients with early POD to guide
treatment decisions. Future studies are needed to pro-
spectively identify patients at risk of early progression
and disease transformation and to design pre-emptive
therapy aimed at improving treatment outcomes and
OS.
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